“Arecor has joined the London Stock Exchange Group’s latest ELITE mission to China for aspiring companies and will participate in investor roadshow events, in Shenzhen and Hong Kong,
between 15th – 18th October 2018”
Cambridge, UK., 15 October 2018: Arecor Limited (“the Company”), the UK-based leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform, is pleased to announce that the Company has joined the London Stock Exchange Group (“LSEG”)’s latest ELITE mission to China for aspiring companies and will participate in investor roadshow events, in Shenzhen and Hong Kong, in addition to meeting separately with key pharmaceutical partners in China.
Dr Sarah Howell, Chief Executive Officer at Arecor, commented: “With China a fast-growing and increasingly important region in the global biopharmaceutical economy, Arecor’s visit to Shenzhen and Hong Kong is both timely and important. Not only does the country offer huge opportunities for companies such as Arecor, in terms of investment and partnering, but it is itself facing significant unmet medical needs – particularly in the diabetes space. We are very excited by the opportunities available in China and its strategic fit with our diabetes portfolio in what is the world’s second largest pharmaceutical market. The Elite programme and the credibility that comes from the LSE has been a great help in getting the right investor contacts in China.”
Click here to view further news items for Arecor: http://arecor.com/2018/